10:47 AM
 | 
Oct 19, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

Acacia provides update on plan to address PONV complete response letter

Acacia Pharma Group plc (Euronext:ACPH) said Oct. 15 that it will complete within one month a plan to address an undisclosed manufacturing deficiency identified by FDA that caused the agency to...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >